Literature DB >> 10785742

Successful Coronary Interventions Performed with Argatroban Anticoagulation in Patients with Heparin-Induced Thrombocytopenia and Thrombosis Syndrome.

.   

Abstract

Patients with heparin-induced thrombocytopenia and thrombosis syndrome (HITTS) frequently have coincident vascular disease. Patients with HITTS who require vascular procedures have often been excluded from vascular intervention because intravascular procedures require heparin. Re-exposure to heparin places these patients at great risk for reactivation of thrombosis related to HIT antibody. We present our initial experience with an alternative anticoagulant to heparin, argatroban in patients with HIT antibody who underwent 14 coronary interventions. All 14 coronary lesions were treated successfully and no patient suffered an HITTS-related or an argatroban-related complication.

Entities:  

Year:  1996        PMID: 10785742

Source DB:  PubMed          Journal:  J Invasive Cardiol        ISSN: 1042-3931            Impact factor:   2.022


  4 in total

Review 1.  A synopsis of the clinical uses of argatroban.

Authors:  M Moledina; M Chakir; P J Gandhi
Journal:  J Thromb Thrombolysis       Date:  2001-10       Impact factor: 2.300

Review 2.  Benefit-risk assessment of treatments for heparin-induced thrombocytopenia.

Authors:  Harry Messmore; Walter Jeske; William Wehrmacher; Jeanine Walenga
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 3.  Thromboprophylaxis with argatroban in critically ill patients with sepsis: a review.

Authors:  Mirjam Bachler; Lars M Asmis; Jürgen Koscielny; Thomas Lang; Hartmuth Nowak; Patrick Paulus; Jens-Christian Schewe; Christian von Heymann; Dietmar Fries
Journal:  Blood Coagul Fibrinolysis       Date:  2022-06-08       Impact factor: 1.061

4.  A Prospective Pilot Trial to Assess the Efficacy of Argatroban (Argatra®) in Critically Ill Patients with Heparin Resistance.

Authors:  Mirjam Bachler; Tobias Hell; Johannes Bösch; Benedikt Treml; Bettina Schenk; Benjamin Treichl; Barbara Friesenecker; Ingo Lorenz; Daniel Stengg; Stefan Hruby; Bernd Wallner; Elgar Oswald; Mathias Ströhle; Christian Niederwanger; Christian Irsara; Dietmar Fries
Journal:  J Clin Med       Date:  2020-03-31       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.